series-c-plus
Stage
2
Investors
About
Inhibrx is a clinical-stage biopharmaceutical company that designs and develops biologic therapeutics using a proprietary single-domain antibody and protein-engineering platform. The company advances targeted immunotherapy and other biologic candidates through clinical development for serious and life‑threatening conditions.
Explore Inhibrx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.